JP2007532596A - Mch拮抗効果を有する新規アルキン化合物及び前記化合物を含有する薬物 - Google Patents
Mch拮抗効果を有する新規アルキン化合物及び前記化合物を含有する薬物 Download PDFInfo
- Publication number
- JP2007532596A JP2007532596A JP2007507709A JP2007507709A JP2007532596A JP 2007532596 A JP2007532596 A JP 2007532596A JP 2007507709 A JP2007507709 A JP 2007507709A JP 2007507709 A JP2007507709 A JP 2007507709A JP 2007532596 A JP2007532596 A JP 2007532596A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- group
- mmol
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DYHVKOMLCLHQEA-UHFFFAOYSA-N CC(C)c(cc12)ccc1OC(C)=CC2=O Chemical compound CC(C)c(cc12)ccc1OC(C)=CC2=O DYHVKOMLCLHQEA-UHFFFAOYSA-N 0.000 description 1
- OMOSCFYSDOBQCA-UHFFFAOYSA-N CC(CC1)CCN1C(CC1)CN1c(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl Chemical compound CC(CC1)CCN1C(CC1)CN1c(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl OMOSCFYSDOBQCA-UHFFFAOYSA-N 0.000 description 1
- ADIYZILNRMBNQP-MHZLTWQESA-N CC(CC1)CCN1[C@@H](CC1)CN1c(cc1)ncc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl Chemical compound CC(CC1)CCN1[C@@H](CC1)CN1c(cc1)ncc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl ADIYZILNRMBNQP-MHZLTWQESA-N 0.000 description 1
- FHRZXQRKVHGZIK-QFIPXVFZSA-N C[C@@H](COc(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl)N1CCC(C)CC1 Chemical compound C[C@@H](COc(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl)N1CCC(C)CC1 FHRZXQRKVHGZIK-QFIPXVFZSA-N 0.000 description 1
- GEKMQIVRSWLRDD-UHFFFAOYSA-N NC(C(CC1)CCN1C(CC1)CN1c(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl)=O Chemical compound NC(C(CC1)CCN1C(CC1)CN1c(cc1)ccc1C#Cc(nc1)ccc1-c(cc1)ccc1Cl)=O GEKMQIVRSWLRDD-UHFFFAOYSA-N 0.000 description 1
- AWHZGSFJGAXLAR-UHFFFAOYSA-N OC(C1CCNCC1)C(F)(F)F Chemical compound OC(C1CCNCC1)C(F)(F)F AWHZGSFJGAXLAR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004017930A DE102004017930A1 (de) | 2004-04-14 | 2004-04-14 | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
PCT/EP2005/003686 WO2005103032A2 (fr) | 2004-04-14 | 2005-04-08 | Nouveaux composes alcyne a effet antagoniste mch, et medicaments contenant ces composes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007532596A true JP2007532596A (ja) | 2007-11-15 |
JP2007532596A5 JP2007532596A5 (fr) | 2008-05-29 |
Family
ID=34964523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507709A Pending JP2007532596A (ja) | 2004-04-14 | 2005-04-08 | Mch拮抗効果を有する新規アルキン化合物及び前記化合物を含有する薬物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1737824A2 (fr) |
JP (1) | JP2007532596A (fr) |
AR (1) | AR048691A1 (fr) |
CA (1) | CA2558755A1 (fr) |
DE (1) | DE102004017930A1 (fr) |
PE (1) | PE20060254A1 (fr) |
TW (1) | TW200538102A (fr) |
UY (1) | UY28852A1 (fr) |
WO (1) | WO2005103032A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532593A (ja) * | 2004-04-14 | 2007-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含有する薬物 |
JP2021523178A (ja) * | 2018-05-11 | 2021-09-02 | ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド | シクロペンタン化合物 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
EP2049472B1 (fr) | 2006-06-23 | 2015-01-21 | AbbVie Bahamas Ltd. | Dérivés de cyclopropylamines comme modulateurs du recepteur h3 de l' histamine |
NZ575520A (en) | 2006-08-25 | 2012-03-30 | Boehringer Ingelheim Int | New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds |
EP2102171A1 (fr) | 2006-12-11 | 2009-09-23 | Boehringer Ingelheim International GmbH | Nouveaux dérivés pyridazines à activité antagoniste du récepteur mch et médicaments comprenant ces composés |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
US20130143869A1 (en) * | 2010-07-16 | 2013-06-06 | Merz Pharma Gmbh & Co. Kgaa | Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue |
WO2012037258A1 (fr) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Procédés de préparation de dérivés cyclopropyliques substitués en 1,2 |
US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
WO2015091741A1 (fr) | 2013-12-19 | 2015-06-25 | Actelion Pharmaceuticals Ltd | Dérivés de 1h-indazole et de 1h-indole antibactériens |
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
EP3532458B1 (fr) | 2016-10-25 | 2021-01-20 | Boehringer Ingelheim International GmbH | Acides benzylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations |
JP7008704B2 (ja) | 2016-11-28 | 2022-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
WO2018138026A1 (fr) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Acides indanylaminopyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations |
EP3573953A1 (fr) | 2017-01-26 | 2019-12-04 | Boehringer Ingelheim International GmbH | Acides benzyloxypyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations |
EP3573952B1 (fr) | 2017-01-26 | 2021-07-14 | Boehringer Ingelheim International GmbH | Acides benzylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées |
US10793530B2 (en) | 2017-01-26 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
CN110312714B (zh) | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856510A (en) * | 1996-12-16 | 1999-01-05 | Allelix Biopharmaceuticals Inc. | 5-alkenyl and 5-alkynyl indole compounds |
JP2001509504A (ja) * | 1997-07-11 | 2001-07-24 | ノバルティス アクチエンゲゼルシャフト | ピリジン誘導体 |
JP2002167382A (ja) * | 2000-07-13 | 2002-06-11 | Sankyo Co Ltd | アミノアルコ−ル誘導体 |
JP2006511492A (ja) * | 2002-10-31 | 2006-04-06 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Mch拮抗活性を有する新規アルキン化合物及びこれらの化合物を含む薬物 |
JP2007532593A (ja) * | 2004-04-14 | 2007-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含有する薬物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7315700A (en) * | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
DK1285651T3 (da) * | 2000-04-28 | 2010-12-13 | Takeda Pharmaceutical | Melanin-koncentrerende hormon-antagonister |
EP1366030A2 (fr) * | 2000-07-06 | 2003-12-03 | Neurogen Corporation | Ligands de recepteur d'hormone a concentration de melanine |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
-
2004
- 2004-04-14 DE DE102004017930A patent/DE102004017930A1/de not_active Withdrawn
-
2005
- 2005-04-08 WO PCT/EP2005/003686 patent/WO2005103032A2/fr not_active Application Discontinuation
- 2005-04-08 CA CA002558755A patent/CA2558755A1/fr not_active Abandoned
- 2005-04-08 JP JP2007507709A patent/JP2007532596A/ja active Pending
- 2005-04-08 EP EP05732062A patent/EP1737824A2/fr not_active Withdrawn
- 2005-04-12 UY UY28852A patent/UY28852A1/es not_active Application Discontinuation
- 2005-04-12 PE PE2005000401A patent/PE20060254A1/es not_active Application Discontinuation
- 2005-04-13 AR ARP050101439A patent/AR048691A1/es unknown
- 2005-04-13 TW TW094111701A patent/TW200538102A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856510A (en) * | 1996-12-16 | 1999-01-05 | Allelix Biopharmaceuticals Inc. | 5-alkenyl and 5-alkynyl indole compounds |
JP2001509504A (ja) * | 1997-07-11 | 2001-07-24 | ノバルティス アクチエンゲゼルシャフト | ピリジン誘導体 |
JP2002167382A (ja) * | 2000-07-13 | 2002-06-11 | Sankyo Co Ltd | アミノアルコ−ル誘導体 |
JP2006511492A (ja) * | 2002-10-31 | 2006-04-06 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Mch拮抗活性を有する新規アルキン化合物及びこれらの化合物を含む薬物 |
JP2007532593A (ja) * | 2004-04-14 | 2007-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含有する薬物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007532593A (ja) * | 2004-04-14 | 2007-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含有する薬物 |
JP2021523178A (ja) * | 2018-05-11 | 2021-09-02 | ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド | シクロペンタン化合物 |
JP7418354B2 (ja) | 2018-05-11 | 2024-01-19 | ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド | シクロペンタン化合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2558755A1 (fr) | 2005-11-03 |
AR048691A1 (es) | 2006-05-17 |
WO2005103032A2 (fr) | 2005-11-03 |
PE20060254A1 (es) | 2006-03-31 |
DE102004017930A1 (de) | 2005-11-03 |
EP1737824A2 (fr) | 2007-01-03 |
UY28852A1 (es) | 2005-11-30 |
TW200538102A (en) | 2005-12-01 |
WO2005103032A3 (fr) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007532596A (ja) | Mch拮抗効果を有する新規アルキン化合物及び前記化合物を含有する薬物 | |
JP4883909B2 (ja) | Mch拮抗活性を有する新規アルキン化合物及びこれらの化合物を含む薬物 | |
US8067590B2 (en) | Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds | |
US8618132B2 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | |
US20070111981A1 (en) | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | |
US7592358B2 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | |
JP2006507246A (ja) | Mch拮抗活性を有する新規カルボキサミド化合物、これらの化合物を含む医薬組成物及びそれらの製造方法 | |
US20050245529A1 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | |
JP2007532594A (ja) | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含む医薬 | |
US7605176B2 (en) | β-ketoamide compounds with MCH antagonistic activity | |
JP2007527424A (ja) | MCH拮抗作用を有するβ−ケトアミド化合物及びこれを含む医薬 | |
JP2007532593A (ja) | Mch拮抗作用を有する新規アルキン化合物及び前記化合物を含有する薬物 | |
US20050267120A1 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | |
US7524862B2 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | |
CA2559698A1 (fr) | Nouveaux composes alkyne a effet antagoniste de mch et medicaments contenant lesdits composes | |
US20050239826A1 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080408 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110516 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111017 |